Value proposition

Together, Re-imagining Gynecology with "Gentle" in Mind.

Aspivix is a medical device company in women’s health, based in Switzerland, developing next-generation devices for gynecology.

Our flagship product, CarevixTM, is the world’s first suction cervical stabilizer clinically proven to reduce pain and bleeding associated with transcervical procedures commonly performed in gynecology, including IUD insertion, hysteroscopy, cervical biopsies, fertility treatments, and more.

CarevixTM is a medical device that has received in 2023 FDA-clearance for the US market, as well as the CE-Mark for the European countries. CarevixTM study published in the international journal, Contraception, in March 2023 demonstrated superiority over the use of a single tooth tenaculum, reducing the pain by up to 73% and the bleeding by up to 83% in IUD insertions.

More than 120 million women worldwide have procedures using the antiquated single-tooth tenaculum, an instrument invented over a century ago, without consideration of a woman's anatomy or pain, and yet it is still considered to be the standard of care in gynecology.

At Aspivix, we think women deserve more. We are driven by our vision to make gynecology modern.

Medical Device, Woman's care, Gynaecology, Woman's health, Medtech, Start-up, Innovation, IUD, Hysteroscopy, Cervical Biopsy, Reproductive Health, FemTech, OBGYN, Midwife, Pain reduction, IVF, Fertility Treatment, and Women's Health